oncotype DX

For patients with early-stage (I, II, or IIIa), HR (hormone receptor)-positive, HER2-negative breast cancer that is either node-negative or node-positive (1-3 nodes).

Reasons to get tested
The Breast Recurrence Score test is the only test proven to predict chemotherapy benefit.
Studies have consistently shown that the Breast Recurrence Score test is the only test that can predict whether or not you'll benefit from chemotherapy.
More than 1.5 million breast, prostate, and colon cancer patients have relied on an Oncotype DX test for insights that help guide their treatment decisions.
Without these tests, your doctors can only estimate how likely your cancer is to return by looking at factors such as age, tumor size, tumor grade, and lymph node status.
The Breast Recurrence Score test is included in every major breast cancer treatment guideline.
Including the National Comprehensive Cancer Network" (NCCN"). American Society of Clinical Oncology (ASCO), the St. Gallen International Consensus Panel, the National Institute for Health and Care Excellence (NICE), and the European Society for Medical Oncology (ESMOJ.
The only genomic test proven to predict a patient’s individual benefit from chemotherapy1,2.

Unique tumors need a uniquely designed test:

  • Provides a Recurrence Score® result, which assesses the expression of 21 genes—16 cancer-related genes and 5 reference genes—in a tumor sample using RT-PCR.3
  • Comprehensive genomic assessment also includes risk of distant recurrence with endocrine therapy alone4
  • Predicts the benefit of adding chemotherapy to endocrine therapy.1,2
  • Provides a quantitative ER Score to help assess the magnitude of hormonal therapy benefit along with additional supporting information such as PR and HER2 scores.3

Gain insight into specific tumor biology, risk assessment, and magnitude of chemotherapy benefit to help inform what’s best for your patient.

Interpreting the Report

Exact Sciences makes understanding the Oncotype Dx Breast Recurrence Score® test result as easy as possible.

Exploratory Subgroup Analysis for TAILORx and NSABP B-20:

Absolute CT Benefit for Distant Recurrence by Age and RS Result.

Included in all major breast cancer treatment guidelines

The Breast Recurrence Score” test is recognized as the standard of care. It’s included in leading oncology guidelines such as the American Society of Clinical Oncology (ASCO®), the National Comprehensive Cancer Network® (NCCN), the St. Gallen Consensus panel, the National Institute for Health Care Excellence (NICE), the European Society for Medical Oncology (ESMO), and the German Association of Gynecological Oncology (AGO).

*American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO: National Comprehensive Cancer Network.

TAILORx provide definitive answers for node-negative patients

The results of the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) definitively identified the 70% of women with early-stage, node-negative breast cancer who will receive no benefit from chemotherapy, and the 30% for whom chemotherapy can be lifesaving.4,11,12

Is Your Patient Eligible?

Patients are eligible for the Breast Recurrence Score test if they are:

  • Recently diagnosed with invasive breast cancer
  • Medically eligible for chemotherapy

And the cancer is:

  • Anatomic stage I, II, or IIIa
  • Hormone receptor-positive (HR+)
  • Human epidermal growth factor receptor-negative (HER2-)
NOTE: Your patients diagnosed with noninvasive breast cancer, ductal carcinoma in situ (DCIS), may be eligible for the Oncotype DX Breast DCIS Score® test.
Test Procedure
Doctor order the test
Collect sample
CHEK Genomics will collect a patient's available tissue sample
Samples are sent to Genomic Health laboratory for analysis
Report releases
Doctors receive results in 10-14 working days *

Breast cancer is considered to be a common malignancy in women, not only in the world but also in Vietnam. However, in recent decades, thanks to the development of molecular diagnostic science, the mortality rate from breast cancer has decreased significantly thanks to the early diagnosis as well as the improvement of treatment regimens. . If you are diagnosed with non-invasive breast cancer (early stage breast cancer), the first treatment will be surgical removal of the tumor. However, after that, the disease recurrence is completely possible if the cancer cells are not completely resolved. Therefore, after surgery, the doctor usually prescribes additional chemotherapy to prevent the possibility of disease recurrence.

Chemotherapy is a treatment that uses anti-cancer drugs to kill cancer cells. The danger is that the drugs and chemicals used in chemotherapy also destroy normal healthy cells. Therefore, besides the ability to treat, chemotherapy also carries a lot of side effects that negatively affect long-term health. So, is chemotherapy essential? While through trials in reality of Montefiore Medical Center New York, 60-70% of breast cancer patients after surgery have suffered unwanted side effects of chemotherapy when this treatment does not have much clinical significance, which means that there is no difference between whether or not chemotherapy is administered.

When considering the best adjuvant treatment option for early-stage breast cancer, the doctor typically take your age, general health, and medical history of you and your family, as well as the size and nature of your tumor into consideration, whether it has invaded any lymph nodes or metastasized to other organs.

Doctors often prescribe a molecular diagnostic test of the tumor by testing the activity of 21 genes directly related to the likelihood of tumor recurrence and response to chemotherapy in tumor tissue. This test, called OncoType DX, has been in use in the US since 2004. The results of the analysis are put into a calculation to give the result “Recurrence Score”, a number ranging from 0 to 100 that provide information about your possibility of breast cancer coming back within 10 years after diagnosis, and it’s more important that whether you get benefits from additional chemotherapy or not.

Is chemotherapy necessary? When does the patient not need chemotherapy?
It is the final result of the test. On a scale from 0 to 100. The higher your score is, the more likely your breast cancer will come back and get benefits from chemotherapy. At this time, adjuvant chemotherapy is more effective in preventing recurrence.


  • Recurrence score from 0-25 and age over 50: Chemotherapy is not effective
  • Recurrence score from 26 and age over 50 : Chemotherapy should be with hormone therapy
  • Recurrence score from 0-15 and age over 50 : Chemotherapy is not effective
  • Recurrence score from 16 and up and Doctors will discuss and combine other factors (family history,
    age less than or equal to 50 environment, etc.) to help you decide whether we get chemotherapy or not?